Literature DB >> 10023771

Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity.

A Glithero1, J Tormo, J S Haurum, G Arsequell, G Valencia, J Edwards, S Springer, A Townsend, Y L Pao, M Wormald, R A Dwek, E Y Jones, T Elliott.   

Abstract

Two synthetic O-GlcNAc-bearing peptides that elicit H-2Db-restricted glycopeptide-specific cytotoxic T cells (CTL) have been shown to display nonreciprocal patterns of cross-reactivity. Here, we present the crystal structures of the H-2Db glycopeptide complexes to 2.85 A resolution or better. In both cases, the glycan is solvent exposed and available for direct recognition by the T cell receptor (TCR). We have modeled the complex formed between the MHC-glycopeptide complexes and their respective TCRs, showing that a single saccharide residue can be accommodated in the standard TCR-MHC geometry. The models also reveal a possible molecular basis for the observed cross-reactivity patterns of the CTL clones, which appear to be influenced by the length of the CDR3 loop and the nature of the immunizing ligand.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10023771     DOI: 10.1016/s1074-7613(00)80007-2

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  29 in total

1.  Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo.

Authors:  J S Haurum; I B Høier; G Arsequell; A Neisig; G Valencia; J Zeuthen; J Neefjes; T Elliott
Journal:  J Exp Med       Date:  1999-07-05       Impact factor: 14.307

2.  Function-related regulation of the stability of MHC proteins.

Authors:  A Simon; Z s Dosztányi; E Rajnavölgyi; I Simon
Journal:  Biophys J       Date:  2000-11       Impact factor: 4.033

3.  Structure-based prediction of binding peptides to MHC class I molecules: application to a broad range of MHC alleles.

Authors:  O Schueler-Furman; Y Altuvia; A Sette; H Margalit
Journal:  Protein Sci       Date:  2000-09       Impact factor: 6.725

Review 4.  A new aspect in glycolipid biology: glycosphingolipids as antigens recognized by T lymphocytes.

Authors:  G De Libero; A Donda; H J Gober; V Manolova; Z Mazorra; A Shamshiev; L Mori
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

5.  A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor.

Authors:  Vasso Apostolopoulos; Elizabeth Yuriev; Paul A Ramsland; Jodie Halton; Carla Osinski; Wenjun Li; Magdalena Plebanski; Hans Paulsen; Ian F C McKenzie
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

6.  Processing of glycans on glycoprotein and glycopeptide antigens in antigen-presenting cells.

Authors:  Ole Werdelin; Morten Meldal; Teis Jensen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-16       Impact factor: 11.205

7.  Discovery of CD8+ T cell epitopes in Chlamydia trachomatis infection through use of caged class I MHC tetramers.

Authors:  Gijsbert M Grotenbreg; Nadia R Roan; Eduardo Guillen; Rob Meijers; Jia-Huai Wang; George W Bell; Michael N Starnbach; Hidde L Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-01       Impact factor: 11.205

8.  Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes.

Authors:  Tanja Ninkovic; Leo Kinarsky; Katja Engelmann; Vladimir Pisarev; Simon Sherman; Olivera J Finn; Franz-Georg Hanisch
Journal:  Mol Immunol       Date:  2008-11-12       Impact factor: 4.407

9.  O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.

Authors:  D Stepensky; E Tzehoval; E Vadai; L Eisenbach
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

10.  Compensatory mechanisms allow undersized anchor-deficient class I MHC ligands to mediate pathogenic autoreactive T cell responses.

Authors:  Deanna Lamont; Gayatri Mukherjee; P Rajesh Kumar; Dibyendu Samanta; Caroline G McPhee; Thomas W H Kay; Steven C Almo; Teresa P DiLorenzo; David V Serreze
Journal:  J Immunol       Date:  2014-07-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.